Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 – 2014). (March 2015)

• Record Type: Journal Article
• Authors: Lee, Yoonji; Hong, Sunhye; Cui, Minghua; Sharma, Pankaz K; Lee, Jeewoo; Choi, Sun
• Is Part Of: Expert opinion on therapeutic patents. Volume 25:Number 3(2015:Mar.)
• Page Start: 291
• Page End: 318
• Publication Date: 2015-03
• Subjects: Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1517/13543776.2015.1008449
• Languages: English
• ISSNs: 1354-3776

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Transient receptor potential vanilloid type 1 (TRPV1) is a nonselective cation channel that can be activated by noxious heat, low pH and vanilloid compounds such as capsaicin. Since TRPV1 acts as an integrator of painful stimuli, TRPV1 antagonists can be used as promising therapeutics for new types of analgesics.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This review article covers the patents that claim TRPV1 antagonists and were published during 2011 – 2014. The patent evaluation is organized according to the applicant companies, and the representative chemical entities with important <italic>in vitro</italic> and <italic>in vivo</italic> data are summarized.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Many pharmaceutical companies showed promising results in the discovery of potent small molecule TRPV1 antagonists, and recently, a number of small molecule TRPV1 antagonists have been advanced into clinical trials. Unfortunately, several candidate molecules showed critical side effects such as hyperthermia and impaired noxious heat sensation in humans, leading to their withdrawal from clinical trials. Some TRPV1 antagonists patented in recent years (2011 – 2014) overcame these undesirable side effects, making the development of TRPV1 antagonists much more promising.</p> </abstract>